Healthcare Professionals Patients
ProAir HFA delivers more than just albuterol

Flexibility, portability, and access for your patients with asthma, COPD, and EIB

ProAir® HFA reliably delivers a consistent metered dose of medication for your patients with asthma, EIB, and COPD. Our albuterol inhaler design suits patients on-the-go. ProAir® HFA delivers a warmer, lower-impact, longer-duration plume—characteristics that may be more desirable.

Inhaled short-acting beta agonists (SABAs) like ProAir® HFA are cornerstones in managing asthma, EIB, and COPD. That's why you'll be glad to know that ProAir® HFA has the widest formulary coverage of any
albuterol HFA inhaler.1

ProAir® HFA (albuterol sulfate) Inhalation Aerosol is indicated in patients 4 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.

Important Safety Information

  • Inhaled albuterol sulfate can produce paradoxical bronchospasm that may be life-threatening. It should be recognized that paradoxical bronchospasm, when associated with inhaled formulations, frequently occurs with the first use of a new canister.
  • Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma.
  • ProAir HFA, as with all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders (especially coronary insufficiency, cardiac arrhythmias, and hypertension), convulsive disorders, hyperthyroidism, and diabetes.
  • Potential drug interactions can occur with beta-blockers, diuretics, digoxin, or monoamine oxidase inhibitors, and tricyclic antidepressants.
  • Do not exceed the recommended dose.
  • Adverse events, which occurred at an incidence rate of at least 3% with ProAir HFA, include headache, tachycardia, pain, dizziness, pharyngitis, and rhinitis.
Reference
  1. Aggregated reports, Formulary Position and Restrictions, ProAir HFA market. Business One Technologies; April 30, 2010.